Oncology drugs for orphan indications: how are HTA processes evolving for this specific drug category?

Orphan drugs (ODs) are intended for the diagnosis, prevention, or treatment of rare diseases. Many cancer subtypes, including all childhood cancers, are defined as rare diseases, and over one-third of ODs are now intended to treat oncology indications. However, market access for oncology ODs is beco...

Descripción completa

Detalles Bibliográficos
Autores principales: Adkins, Elizabeth M, Nicholson, Lindsay, Floyd, David, Ratcliffe, Mark, Chevrou-Severac, Helene
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5473500/
https://www.ncbi.nlm.nih.gov/pubmed/28652787
http://dx.doi.org/10.2147/CEOR.S134230

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5473500/
https://www.ncbi.nlm.nih.gov/pubmed/28652787
http://dx.doi.org/10.2147/CEOR.S134230

Ejemplares similares